Cargando…

Evaluation of buprenorphine/naloxone dose and use of sedating supportive medication on treatment outcomes in veterans with opioid use disorder

INTRODUCTION: This retrospective cohort study evaluated effects of buprenorphine/naloxone dose and concomitant use of selected sedating medications on treatment outcomes in patients with opioid use disorder. METHODS: Patients enrolled in the buprenorphine/naloxone clinic at the study institution fro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kapuganti, Amber, Turner, Traci, Thomas, Christopher J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	College of Psychiatric & Neurologic Pharmacists 2018
Materias:	Opioid Abuse
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007732/ https://www.ncbi.nlm.nih.gov/pubmed/29955533 http://dx.doi.org/10.9740/mhc.2017.11.271

Ejemplares similares

Implementation and results of a symptom-triggered opioid withdrawal protocol at a Veterans Affairs medical center
por: Koch, Jessa, et al.
Publicado: (2018)

A retrospective chart review of opioid represcribing following nonfatal overdose at a Veterans Affairs hospital
por: Boyle, Julia, et al.
Publicado: (2018)

Evaluation of the Tolerability of Switching Patients on Chronic Full μ-Opioid Agonist Therapy to Buccal Buprenorphine
por: Webster, Lynn, et al.
Publicado: (2016)

Using machine learning to advance disparities research: Subgroup analyses of access to opioid treatment
por: Kong, Yinfei, et al.
Publicado: (2021)

Relapse rates among veterans on maintenance doses of combination buprenorphine and naloxone for opioid use disorder
por: Binger, Katie J., et al.
Publicado: (2020)

Consensus Recommendations on Initiating Prescription Therapies for Opioid‐Induced Constipation
por: Argoff, Charles E., et al.
Publicado: (2015)

ER/LA Opioid Analgesics REMS: Overview of Ongoing Assessments of Its Progress and Its Impact on Health Outcomes
por: Cepeda, M. Soledad, et al.
Publicado: (2017)

Oral Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users
por: Harris, Stephen C., et al.
Publicado: (2017)

Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
por: Darwish, Mona, et al.
Publicado: (2017)

Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users
por: Setnik, Beatrice, et al.
Publicado: (2017)

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
por: Kanervo, Minna M., et al.
Publicado: (2022)

Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users
por: Smith, Michael D., et al.
Publicado: (2017)

Dancing with Deterrents: Understanding the Role of Abuse‐Deterrent Opioid Formulations and Naloxone in Managing Cancer Pain
por: Mitchell, Megan T.
Publicado: (2019)

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men
por: Ziaaddini, Hassan, et al.
Publicado: (2018)

A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone
por: Webster, Lynn R., et al.
Publicado: (2016)

Diversion and Illicit Sale of Extended Release Tapentadol in the United States
por: Dart, Richard C., et al.
Publicado: (2016)

One Month of Oral Morphine Decreases Gray Matter Volume in the Right Amygdala of Individuals with Low Back Pain: Confirmation of Previously Reported Magnetic Resonance Imaging Results
por: Lin, Joanne C., et al.
Publicado: (2016)

Buprenorphine/naloxone access for people with opioid use disorder in correctional facilities: taking steps to support knowledge translation
por: Regenstreif, Lori, et al.
Publicado: (2022)

Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion
por: Webster, Lynn, et al.
Publicado: (2020)

Successful Management of Kratom Use Disorder With Buprenorphine and Naloxone
por: Arhin, Martin, et al.
Publicado: (2023)

Reconsidering the Usefulness of Adding Naloxone to Buprenorphine
por: Blazes, Christopher K., et al.
Publicado: (2020)

Evaluation of the Effectiveness of Buprenorphine-Naloxone on Opioid Overdose and Death among Insured Patients with Opioid Use Disorder in the United States
por: Sun, Tianyu, et al.
Publicado: (2022)

Utilizing buprenorphine–naloxone to treat illicit and prescription-opioid dependence
por: Mauger, Sofie, et al.
Publicado: (2014)

Sexual Adverse Effects and Erectile Dysfunction During Buprenorphine/Naloxone Combination Treatment for Opioid Use Disorders
por: Bestepe, Engin Emrem, et al.
Publicado: (2020)

Nicotine Gateway Effects on Adolescent Substance Use
por: Ren, Michelle, et al.
Publicado: (2019)

Practical Considerations for the Clinical Use of Buprenorphine
por: Jones, Hendrée E.
Publicado: (2004)

Record Linkage Approaches Using Prescription Drug Monitoring Program and Mortality Data for Public Health Analyses and Epidemiologic Studies
por: Nechuta, Sarah, et al.
Publicado: (2020)

Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization
por: Gu, Meng, et al.
Publicado: (2023)

Prevalence of Current Restless Legs Syndrome Symptoms Among Patients Treated with Buprenorphine/Naloxone for Opioid Use Disorder
por: Wipper, Benjamin, et al.
Publicado: (2023)

New developments in the management of opioid dependence: focus on sublingual buprenorphine–naloxone
por: Soyka, Michael
Publicado: (2015)

Opioid Drug Utilization and Cost Outcomes Associated With the Use of Buprenorphine-Naloxone in Patients With a History of Prescription Opioid Use
por: Kaur, Aman Deep, et al.
Publicado: (2008)

Navigating Challenging Conversations About Nonmedical Opioid Use in the Context of Oncology
por: Sager, Zachary, et al.
Publicado: (2019)

Child abuse in children living with special guardians, a service evaluation of child protection medical examinations
por: Garstang, Joanna, et al.
Publicado: (2021)

A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes
por: Lund, Ingunn O., et al.
Publicado: (2013)

Risk Factors for Serious Prescription Opioid-Induced Respiratory Depression or Overdose: Comparison of Commercially Insured and Veterans Health Affairs Populations
por: Nadpara, Pramit A, et al.
Publicado: (2018)

Is Buprenorphine-Naloxone Ready for Prime Time in the Treatment of Opioid Addiction in Managed Care?
por: Curtiss, Frederic R.
Publicado: (2008)

Low-dose naloxone provides an abuse-deterrent effect to buprenorphine
por: Webster, Lynn R, et al.
Publicado: (2015)

The use of buprenorphine/naloxone to treat borderline personality disorder: a case report
por: Hansen, Brenna, et al.
Publicado: (2022)

Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial
por: Bastien, Gabriel, et al.
Publicado: (2022)

Comment on “A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence During Pregnancy: Maternal and Neonatal Outcomes”
por: Newman, Robert G., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_j2bmjqdqisf7508rk9kur1fe5d